Oregon Clinical Trials

A listing of Oregon clinical trials actively recruiting patient volunteers.

Perhaps best known to generations of children for the Oregon Trail, a nearly 2,200-mile wagon route from Missouri to Oregon, the trail’s terminus of Oregon City remains one of the state’s largest cities today. Its capital is Salem, while its other big cities include Portland and Eugene. The state borders the Pacific Ocean, while the Columbia River forms its northern border with Washington. These days it is increasingly staking out a reputation as a regional leader on the healthcare front. The 552-bed Providence St. Vincent Medical Center in Beaverton, OR is the state’s largest largest facility for acute patient care.

Filter by Condition
1238 trials found

Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema

NCT04697758

This study is an open-label, dose-escalating, 48-week study assessing the safety, tolerability, bioactivity and duration of action of a single intravitreal injection of 0.1 mg, 0.25 mg, or 0.5 mg AXT107 in approximately 18 subjects (up to 6 subjects per dose) with Diabetic Macular Edema (DME).

Conditions: Diabetic Macular Edema (DME)
Phase: Phase 1/2

A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)

NCT04688164

This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as an adjunctive treatment of Major Depressive Disorder. Study participants will continue to take their current antidepressant therapy in addition to the study drug or placebo for the duration of the treatment period.

Conditions: Major Depressive Disorder

Demineralized Bone Matrix Rotator Cuff Study

NCT04686396

Patients undergoing rotator cuff repair surgery will experience improved tendon healing with the use of demineralized bone matrix augmentation.

Conditions: Rotator Cuff Injuries
Phase: Not Applicable

Cardiogenic Shock Working Group Registry

NCT04682483

The Cardiogenic Shock Working Group is a multicenter registry where we collect de-identified clinical variables from the medical records and follow-up phone calls of shock patients from multiple institutions and centralize this data to a single registry for analysis of clinical outcomes.

Conditions: Cardiogenic Shock

SCS as an Option for Chronic Low Back and/or Leg Pain Instead of Surgery

NCT04676022

To evaluate the safety and effectiveness of Spinal Cord Stimulation (SCS) with multiple modalities compared to Conventional Medical Management (CMM) in patients with chronic low back and/or leg pain who have not undergone spinal surgery when using the Boston Scientific WaveWriter SCS Systems.

Conditions: Chronic Pain
Phase: Not Applicable

AB-101 as Monotherapy and In Combination With Rituximab in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

NCT04673617

AB-101 is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that are known to kill cancer cells. This clinical trial is conducted in two phases. The primary objective of Phase 1 is to test the safety of AB-101 given alone or in combination with rituximab. The primary objective of Phase 2 is to determine if AB-101 in combination with rituximab has activity in ...

Conditions: Non Hodgkin Lymphoma
Phase: Phase 1/2

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

NCT04658862

The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy.

Conditions: Urinary Bladder Neoplasms

ASCO Survey on COVID-19 in Oncology (ASCO) Registry

NCT04659135

The American Society of Clinical Oncology (ASCO) Survey on Coronavirus 2019 (COVID-19) in Oncology Registry (ASCO Registry) aims to help the cancer community learn more about the patterns of symptoms and severity of COVID-19 among patients with cancer, as well as how COVID-19 is impacting the delivery of cancer care and patient outcomes. The ASCO Registry is designed to collect both baseline and follow-up data on how the virus impacts cancer care and cancer patient outcomes during the COVID-19 p ...

Conditions: Neoplasms, Coronavirus

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

NCT04649242

The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.

Conditions: Migraine

Restore EF Observational Study

NCT04648306

A multi-center, prospective, observational, non-interventional single arm, study of the intermediate-term clinical outcomes collected from electronic health records of high-risk patients which have previously undergone standard of care prophylactic Impella support for a non-emergent percutaneous coronary intervention (PCI).

Conditions: Coronary Artery Disease, Unstable Angina, Angina, Stable, NSTEMI - Non-ST Segment Elevation MI

A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration

NCT04643886

This study is designed to investigate the safety, PK/PD, biomarker and early clinical effects of repeat GEM103 IVT injections.

Conditions: Dry Age-related Macular Degeneration, Geographic Atrophy, Macular Degeneration, Retinal Disease, Retinal Degeneration

Adaptive COVID-19 Treatment Trial 4 (ACTT-4)

NCT04640168

ACTT-4 will evaluate the combination of baricitinib and remdesivir compared to dexamethasone and remdesivir. Subjects will be assessed daily while hospitalized. If the subjects are discharged from the hospital, they will have a study visit at Days 15, 22, and 29. For discharged subjects, it is preferred that the Day 15 and 29 visits are in person to obtain safety laboratory tests, oropharyngeal (OP) swabs, plasma (Day 29), and serum for secondary research as well as clinical outcome data. Howeve ...

Conditions: COVID-19